Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder

Melinda Westlund Schreiner; Bonnie Klimes-Dougan; Bryon A Mueller; Kaz J Nelson; Kelvin O Lim; Kathryn R Cullen

doi:10.1016/j.pscychresns.2019.07.001

Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder

Melinda Westlund Schreiner, Bonnie Klimes-Dougan, Bryon A Mueller, Kaz J Nelson, Kelvin O Lim, Kathryn R Cullen

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Borderline personality disorder (BPD) is a serious illness associated with chronic suffering and self-injurious behavior. Parsing the relationships between specific symptom domains and their underlying biological mechanisms may help us further understand the neural circuits implicated in these symptoms and how they might be amenable to change with treatment. This study examines the association between symptom dimensions (Affective Disturbance, Cognitive Disturbance, Disturbed Relationships, and Impulsivity) and amygdala resting-state functional connectivity (RSFC) in a sample of adults with BPD (n = 18). We also explored the relationships between change in symptom dimensions and change in amygdala RSFC in a subset of this sample (n = 13) following 8 weeks of quetiapine or placebo. At baseline, higher impulsivity was associated with increased positive RSFC between right amygdala and left hippocampus. There were no significant differences in neural change between treatment groups. Improvement in cognitive disturbance was associated with increased positive RSFC between left amygdala and temporal fusiform and parahippocampal gyri. Improvement in disturbed relationships was associated with increased negative RSFC between right amygdala and frontal pole. These results support that specific dimensions of BPD are associated with specific neural connectivity patterns at baseline and with change, which may represent neural treatment targets.

Original language	English (US)
Pages (from-to)	58-65
Number of pages	8
Journal	Psychiatry Research - Neuroimaging
Volume	290
DOIs	https://doi.org/10.1016/j.pscychresns.2019.07.001
State	Published - Aug 30 2019

Bibliographical note

Funding Information:
The authors thank all participants who contributed their time and effort for the present study as well as research staff that assisted with data collection including Alaa Houri, Ann Romine, and Ana Westervelt. Finally, the authors thank the late Dr. S. Charles Schulz for his work in the funding, design, and conceptualization of the present study. This study was supported in part by an investigator-initiated grant awarded to Dr. S. Charles Schulz from AstraZeneca ( D1443C00097 / IRUSQUET0454 ) to conduct the double-blind placebo-controlled trial portion of the study. These funds were also used for recruitment and clinical assessment. Neuroimaging costs for the present study were supported by internal funds through the University of Minnesota. AstraZeneca did not contribute to the study design or data collection, analysis, and interpretation. AstraZeneca also did not contribute to the decision to submit the article for publication.

Publisher Copyright:
© 2019 Elsevier B.V.

Keywords

Borderline personality disorder
Neuroimaging
Resting-state functional connectivity
Symptom dimension

Access

10.1016/j.pscychresns.2019.07.001

OpenUrl availability

Full text

Cite this

@article{17b8cba50ff54e31b62bd6cadc07ea95,

title = "Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder",

abstract = "Borderline personality disorder (BPD) is a serious illness associated with chronic suffering and self-injurious behavior. Parsing the relationships between specific symptom domains and their underlying biological mechanisms may help us further understand the neural circuits implicated in these symptoms and how they might be amenable to change with treatment. This study examines the association between symptom dimensions (Affective Disturbance, Cognitive Disturbance, Disturbed Relationships, and Impulsivity) and amygdala resting-state functional connectivity (RSFC) in a sample of adults with BPD (n = 18). We also explored the relationships between change in symptom dimensions and change in amygdala RSFC in a subset of this sample (n = 13) following 8 weeks of quetiapine or placebo. At baseline, higher impulsivity was associated with increased positive RSFC between right amygdala and left hippocampus. There were no significant differences in neural change between treatment groups. Improvement in cognitive disturbance was associated with increased positive RSFC between left amygdala and temporal fusiform and parahippocampal gyri. Improvement in disturbed relationships was associated with increased negative RSFC between right amygdala and frontal pole. These results support that specific dimensions of BPD are associated with specific neural connectivity patterns at baseline and with change, which may represent neural treatment targets.",

keywords = "Borderline personality disorder, Neuroimaging, Resting-state functional connectivity, Symptom dimension",

author = "{Westlund Schreiner}, Melinda and Bonnie Klimes-Dougan and Mueller, {Bryon A} and Nelson, {Kaz J} and Lim, {Kelvin O} and Cullen, {Kathryn R}",

note = "Funding Information: The authors thank all participants who contributed their time and effort for the present study as well as research staff that assisted with data collection including Alaa Houri, Ann Romine, and Ana Westervelt. Finally, the authors thank the late Dr. S. Charles Schulz for his work in the funding, design, and conceptualization of the present study. This study was supported in part by an investigator-initiated grant awarded to Dr. S. Charles Schulz from AstraZeneca ( D1443C00097 / IRUSQUET0454 ) to conduct the double-blind placebo-controlled trial portion of the study. These funds were also used for recruitment and clinical assessment. Neuroimaging costs for the present study were supported by internal funds through the University of Minnesota. AstraZeneca did not contribute to the study design or data collection, analysis, and interpretation. AstraZeneca also did not contribute to the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2019",

month = aug,

day = "30",

doi = "10.1016/j.pscychresns.2019.07.001",

language = "English (US)",

volume = "290",

pages = "58--65",

journal = "Psychiatry Research - Neuroimaging",

issn = "0925-4927",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder

AU - Westlund Schreiner, Melinda

AU - Klimes-Dougan, Bonnie

AU - Mueller, Bryon A

AU - Nelson, Kaz J

AU - Lim, Kelvin O

AU - Cullen, Kathryn R

N1 - Funding Information: The authors thank all participants who contributed their time and effort for the present study as well as research staff that assisted with data collection including Alaa Houri, Ann Romine, and Ana Westervelt. Finally, the authors thank the late Dr. S. Charles Schulz for his work in the funding, design, and conceptualization of the present study. This study was supported in part by an investigator-initiated grant awarded to Dr. S. Charles Schulz from AstraZeneca ( D1443C00097 / IRUSQUET0454 ) to conduct the double-blind placebo-controlled trial portion of the study. These funds were also used for recruitment and clinical assessment. Neuroimaging costs for the present study were supported by internal funds through the University of Minnesota. AstraZeneca did not contribute to the study design or data collection, analysis, and interpretation. AstraZeneca also did not contribute to the decision to submit the article for publication. Publisher Copyright: © 2019 Elsevier B.V.

PY - 2019/8/30

Y1 - 2019/8/30

N2 - Borderline personality disorder (BPD) is a serious illness associated with chronic suffering and self-injurious behavior. Parsing the relationships between specific symptom domains and their underlying biological mechanisms may help us further understand the neural circuits implicated in these symptoms and how they might be amenable to change with treatment. This study examines the association between symptom dimensions (Affective Disturbance, Cognitive Disturbance, Disturbed Relationships, and Impulsivity) and amygdala resting-state functional connectivity (RSFC) in a sample of adults with BPD (n = 18). We also explored the relationships between change in symptom dimensions and change in amygdala RSFC in a subset of this sample (n = 13) following 8 weeks of quetiapine or placebo. At baseline, higher impulsivity was associated with increased positive RSFC between right amygdala and left hippocampus. There were no significant differences in neural change between treatment groups. Improvement in cognitive disturbance was associated with increased positive RSFC between left amygdala and temporal fusiform and parahippocampal gyri. Improvement in disturbed relationships was associated with increased negative RSFC between right amygdala and frontal pole. These results support that specific dimensions of BPD are associated with specific neural connectivity patterns at baseline and with change, which may represent neural treatment targets.

AB - Borderline personality disorder (BPD) is a serious illness associated with chronic suffering and self-injurious behavior. Parsing the relationships between specific symptom domains and their underlying biological mechanisms may help us further understand the neural circuits implicated in these symptoms and how they might be amenable to change with treatment. This study examines the association between symptom dimensions (Affective Disturbance, Cognitive Disturbance, Disturbed Relationships, and Impulsivity) and amygdala resting-state functional connectivity (RSFC) in a sample of adults with BPD (n = 18). We also explored the relationships between change in symptom dimensions and change in amygdala RSFC in a subset of this sample (n = 13) following 8 weeks of quetiapine or placebo. At baseline, higher impulsivity was associated with increased positive RSFC between right amygdala and left hippocampus. There were no significant differences in neural change between treatment groups. Improvement in cognitive disturbance was associated with increased positive RSFC between left amygdala and temporal fusiform and parahippocampal gyri. Improvement in disturbed relationships was associated with increased negative RSFC between right amygdala and frontal pole. These results support that specific dimensions of BPD are associated with specific neural connectivity patterns at baseline and with change, which may represent neural treatment targets.

KW - Borderline personality disorder

KW - Neuroimaging

KW - Resting-state functional connectivity

KW - Symptom dimension

UR - http://www.scopus.com/inward/record.url?scp=85068565759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068565759&partnerID=8YFLogxK

U2 - 10.1016/j.pscychresns.2019.07.001

DO - 10.1016/j.pscychresns.2019.07.001

M3 - Article

C2 - 31302291

AN - SCOPUS:85068565759

SN - 0925-4927

VL - 290

SP - 58

EP - 65

JO - Psychiatry Research - Neuroimaging

JF - Psychiatry Research - Neuroimaging

ER -

Neurocircuitry associated with symptom dimensions at baseline and with change in borderline personality disorder

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this